We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Innovative application of an existing drug offers promising alternative treatment to traditional chemotherapy for patients with appendix cancer.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Steroids, hyaluronic acid injections, and regenerative therapies, such as PRP and stem cell injections, are among the ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

In a perspective article published in Science, Professor Jonathan Rivnay explores next-generation bioelectronic medication.

We recently published a list of 10 Most Promising Low-Cost Stocks According to Hedge Funds. In this article, we are going to ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

The Department of Pharmaceuticals (DoP) has dismissed two review applications filed by Abbott Healthcare Private Limited ...